Replay's HSV platform has incredible potential in a variety of human diseases and disorders.
For our first product, we have chosen to tackle a rare skin disorder known as DEB (Dystrophic Epidermolysis Bullosa), which is caused by mutations in the gene encoding type VII collagen (COL7A1). We are poised to complete our pre-clinical studies and meet with regulatory agencies to discuss our plans for the Phase 1 study.
For now, we are keeping the pipeline plans confidential, but will share more in due course.